Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. is an American pharmaceutical company that develops therapeutics for select chronic diseases utilizing its innovative, long-term, continuous drug delivery platform, ProNeura. The company's primary asset is Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction.

History

Titan Pharmaceuticals was founded in 1992 in South San Francisco, California. The company was initially focused on the development of treatments for central nervous system disorders. Over the years, Titan has shifted its focus towards the development of therapeutics for the treatment of chronic diseases, with a particular emphasis on opioid addiction.

ProNeura Technology

Titan's ProNeura technology is a long-term, continuous drug delivery system that consists of a small, solid implant made from a mixture of ethylene-vinyl acetate and a drug substance. The implant is inserted subdermally and is designed to deliver drugs at a stable, continuous rate for up to six months.

Probuphine

Probuphine is Titan's lead product, which utilizes the ProNeura technology to deliver buprenorphine, a partial opioid agonist, for the long-term maintenance treatment of opioid addiction. Probuphine was approved by the U.S. Food and Drug Administration (FDA) in 2016.

Financials

Titan Pharmaceuticals is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol "TTNP". The company's financial performance is subject to the typical risks and uncertainties associated with the pharmaceutical industry, including the success of its research and development efforts, the approval and market acceptance of its products, and the level of competition in the market.

See also

• Pharmaceutical industry in the United States
• Opioid epidemic in the United States